IL148900A0 - Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna - Google Patents

Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna

Info

Publication number
IL148900A0
IL148900A0 IL14890000A IL14890000A IL148900A0 IL 148900 A0 IL148900 A0 IL 148900A0 IL 14890000 A IL14890000 A IL 14890000A IL 14890000 A IL14890000 A IL 14890000A IL 148900 A0 IL148900 A0 IL 148900A0
Authority
IL
Israel
Prior art keywords
recombinant cells
hiv
triplex dna
dna
vectors
Prior art date
Application number
IL14890000A
Other languages
English (en)
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Publication of IL148900A0 publication Critical patent/IL148900A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14890000A 1999-10-12 2000-10-10 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna IL148900A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15838799P 1999-10-12 1999-10-12
PCT/EP2000/010418 WO2001027304A2 (en) 1999-10-12 2000-10-10 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna

Publications (1)

Publication Number Publication Date
IL148900A0 true IL148900A0 (en) 2002-09-12

Family

ID=22567880

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14890000A IL148900A0 (en) 1999-10-12 2000-10-10 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
IL148900A IL148900A (en) 1999-10-12 2002-03-26 HIV - 1 EXPRESSION VECTOR COMPRISING THE cPPT AND CTS cis- ACTING REGIONS OF A RETROVIRUS AND A HETEROLOGOUS NUCLEIC ACID SEQUENCE
IL198076A IL198076A (en) 1999-10-12 2009-04-07 USE OF A RETROVIRAL VECTOR COMPRISING cPPT AND CTS REGIONS OF LENTIVIRAL AND A RETROVIRAL VECTOR

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL148900A IL148900A (en) 1999-10-12 2002-03-26 HIV - 1 EXPRESSION VECTOR COMPRISING THE cPPT AND CTS cis- ACTING REGIONS OF A RETROVIRUS AND A HETEROLOGOUS NUCLEIC ACID SEQUENCE
IL198076A IL198076A (en) 1999-10-12 2009-04-07 USE OF A RETROVIRAL VECTOR COMPRISING cPPT AND CTS REGIONS OF LENTIVIRAL AND A RETROVIRAL VECTOR

Country Status (15)

Country Link
US (7) US8093042B2 (pt)
EP (2) EP1224314B1 (pt)
JP (1) JP4436024B2 (pt)
CN (2) CN100425702C (pt)
AT (2) ATE351916T1 (pt)
AU (2) AU784910B2 (pt)
CA (1) CA2382832C (pt)
CY (2) CY1106513T1 (pt)
DE (1) DE60033045T2 (pt)
DK (2) DK1224314T3 (pt)
ES (2) ES2280250T3 (pt)
HK (2) HK1050210B (pt)
IL (3) IL148900A0 (pt)
PT (2) PT1792997E (pt)
WO (1) WO2001027304A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
PT2169073E (pt) 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
PT1792997E (pt) * 1999-10-12 2012-02-02 Pasteur Institut Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
CA2915676C (en) 2001-10-02 2017-06-06 Institut Clayton De La Recherche Restricted expression lentiviral vectors
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP2643343A1 (en) 2010-11-26 2013-10-02 Institut Pasteur Identification of a human gyrovirus and applications.
ES2651922T3 (es) 2011-11-08 2018-01-30 Institut Pasteur Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
CA2927712A1 (en) * 2013-10-24 2015-04-30 Ospedale San Raffaele S.R.L. Method for the genetic modification of haematopoietic stem and progenitor cells (hspcs) and the use of genetically modified hspcs in gene therapy
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
ES2777534T3 (es) 2015-02-13 2020-08-05 Inserm - Institut National De La Santé Et De La Rech Médicale Polipéptidos para la ingeniería de proteínas integrasas quiméricas y su uso en terapia génica
BR112018010639A2 (pt) 2015-11-24 2019-01-22 Glaxosmithkline Ip Dev Ltd método de transfecção transitória para produção retroviral.
EP3211003A1 (en) 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11286501B2 (en) 2016-04-20 2022-03-29 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas O.A, M.P. Methods of treating or preventing pyruvate kinase deficiency
JP7424748B2 (ja) * 2016-06-22 2024-01-30 イエール ユニバーシティ 植物薬についての、機序に基づく質管理
EP3357506A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
EP3357504A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
MX2020003954A (es) 2017-10-16 2020-10-05 Consorcio Centro De Investig Biomedica En Red M P Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
JP2021520853A (ja) 2018-04-12 2021-08-26 ウモジャ バイオファーマ， インコーポレイテッド ウイルスベクター及びパッケージング細胞株
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
EP3884058A1 (en) 2018-11-21 2021-09-29 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20220143634A (ko) 2019-10-16 2022-10-25 우모자 바이오파마 인코포레이티드 보편적 수용체 요법을 위한 레트로바이러스 벡터
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2022015955A1 (en) 2020-07-16 2022-01-20 Umoja Biopharma, Inc. Gated adapter targeting receptor
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (en) 2020-10-16 2022-04-20 Institut Pasteur Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
WO2022109162A1 (en) 2020-11-20 2022-05-27 Umoja Biopharma, Inc. Vector system for delivery of multiple polynucleotides and uses thereof
CA3209285A1 (en) 2021-03-12 2022-09-15 Pierre Charneau Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
AU2022414186A1 (en) 2021-12-17 2024-07-11 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023240282A1 (en) 2022-06-10 2023-12-14 Umoja Biopharma, Inc. Engineered stem cells and uses thereof
TW202423456A (zh) 2022-10-21 2024-06-16 法商賽拉福柯蒂斯公司 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6004799A (en) * 1996-03-05 1999-12-21 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral DNA vaccines
WO1998046083A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
PT2169073E (pt) 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
PT1792997E (pt) 1999-10-12 2012-02-02 Pasteur Institut Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
EP1224314B1 (en) 2007-01-17
CN101363029A (zh) 2009-02-11
CN100425702C (zh) 2008-10-15
US20150191745A1 (en) 2015-07-09
US20150011006A1 (en) 2015-01-08
ES2377721T3 (es) 2012-03-30
CY1106513T1 (el) 2012-01-25
US9238824B2 (en) 2016-01-19
US8512994B2 (en) 2013-08-20
CY1112430T1 (el) 2015-12-09
DE60033045D1 (de) 2007-03-08
ES2280250T3 (es) 2007-09-16
WO2001027304A3 (en) 2001-11-29
JP2003511083A (ja) 2003-03-25
HK1050210B (zh) 2007-08-24
CA2382832A1 (en) 2001-04-19
WO2001027304A2 (en) 2001-04-19
EP1792997A1 (en) 2007-06-06
EP1224314A2 (en) 2002-07-24
US10407695B2 (en) 2019-09-10
CA2382832C (en) 2012-06-26
IL198076A (en) 2011-12-29
DE60033045T2 (de) 2007-11-08
JP4436024B2 (ja) 2010-03-24
US20180346928A1 (en) 2018-12-06
AU7921700A (en) 2001-04-23
US20120122204A1 (en) 2012-05-17
ATE351916T1 (de) 2007-02-15
IL148900A (en) 2009-11-18
HK1109167A1 (en) 2008-05-30
US20190119699A1 (en) 2019-04-25
CN101363029B (zh) 2016-01-13
US8512993B2 (en) 2013-08-20
US8093042B2 (en) 2012-01-10
CN1402793A (zh) 2003-03-12
AU2006233199A1 (en) 2006-11-23
AU2006233199B2 (en) 2009-07-23
US20070224679A1 (en) 2007-09-27
DK1224314T3 (da) 2007-05-21
PT1792997E (pt) 2012-02-02
EP1792997B1 (en) 2011-11-02
DK1792997T3 (da) 2012-01-30
ATE531808T1 (de) 2011-11-15
AU784910B2 (en) 2006-07-27
HK1050210A1 (en) 2003-06-13
PT1224314E (pt) 2007-04-30
US20120122963A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
HK1109167A1 (en) Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
DK0797678T3 (da) Hybrid adenovirus-AAV-virus og fremgangsmåder til anvendelse af dette
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
FR2777909B1 (fr) Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP0851769A4 (en) GENE THERAPY WITH THE HELP OF SHEEP ADENOVIRAL VECTORS
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
ATE475713T1 (de) Trans-lentivirales vektor system
EP2145961A3 (en) Porcine adenovirus type 3 genome
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
AU630861B2 (en) Recombinant hiv-2 polypeptides
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
IL149704A0 (en) Bovine immunodeficiency virus (biv) based vectors
FR2607518B1 (fr) Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen
JPS6485072A (en) Recombinant vaccinia virus
Scheiflinger et al. A new vaccinia recombinant plasmid pSC-O
ATE417108T1 (de) Hiv-2 und siv-1 nukleotidsequenzen
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins